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a b s t r a c t
Cytokines of the IL-6 family have been related to infarct size and prognosis in patients with myocardial
infarction. The aims of the present study were to elucidate possible associations between myocardial
necrosis and left ventricular impairment and members of the IL-6 transsignalling system including
soluble (s) IL-6R and (s) glycoprotein 130 (sgp130) in patients with ST-elevation myocardial infarction
(STEMI) treated with primary PCI.
In blood samples from 1028 STEMI patients, collected in-hosptial, we found signiﬁcant correlations
between peak TnT and IL-6 and CRP (p o 0.001, all) and between IL-6 and CRP and LV ejection fraction
and NT-proBNP (p o 0.001, all). On the contrary, no signiﬁcant associations were found between peak
TnT and sgp130 or sIL-6R. Furthermore sgp130 was signiﬁcantly elevated in diabetic patients and also
associated with the glucometabolic state.
In conclusion, circulating levels of IL-6 and CRP, but not the soluble forms of the receptor (sIL-6R) or the
receptor signalling subunit (sgp130) were associated with the extent of myocardial necrosis. The
biological importance of the IL-6/gp130-mediated signalling pathways in patients with acute myocardial
infarction and dysglycemia should be further elucidated.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Atherosclerosis is now regarded as an inﬂammatory disease.
Inﬂammation in the vessel wall seems to be important for the
development of the atherosclerotic plaque as well as for plaque
destabilisation [1,2]. Inﬂammation also seems to be involved in the
remodelling process after acute STEMI [3]. The complexity of the
atherosclerotic process and the regulatory mechanisms involving
inﬂammation are only partly understood [3,4]. However, cytokines
of the IL-6 family have been shown to play a role in all stages of
the development and progression of atherosclerosis, from early
inﬂammatory lesions to destabilisation of the plaque [5]. Pro-
inﬂammatory cytokines are thought to be involved in reperfusion
injury, repair processes and scar tissue formation after myocardial
infarction [3]. Circulating levels of IL-6 and C-reactive protein
(CRP) have been shown to correlate with infarct size [6], whereas
the knowledge of other novel members of the IL-6 family like
soluble interleukin-6 receptor (sIL-6R) and soluble glycoprotein
130 (sgp130) is limited in patients with myocardial infarction.
The IL-6 signalling is activated through two different ways and
it has been a matter of discussion whether this results in both a
pro- and anti-inﬂammatory effect of IL-6 [7].
In the classical IL-6 signalling pathway IL-6 binds to IL-6R,
which is a membrane-bound receptor on the cell surface [8]. The
receptor–ligand complex then associates with the common signal
transducing receptor gp130, initiating activation of intracellular
signalling pathways. The membrane-bound IL-6R is present in
cells like hepatocytes, monocytes, inactive B and T-lymphocytes
[8] and cardiac myocytes [9] whereas gp130 is widely expressed in
most cell types in the human body. In the second way of IL-6
signalling, which has been named the transsignalling system, IL-6
binds to a soluble form of IL-6R (sIL-6R), and this complex binds
subsequently to gp130 on cells. The gp130/IL6/sIL-6R complex
activates intracellular pathways, and exerts its function in cells not
expressing the IL-6R [10]. This IL-6 transsignalling pathway may
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be more important for the pro-inﬂammatory effect of IL-6 than the
classical receptor signalling [7]. The soluble form of gp130
(sgp130) is the natural inhibitor of this transsignalling system
[11]. It inhibits the ability of the circulating IL-6/sIL-6R complex to
bind to membrane bound gp130.
These less studied members of the IL-6 signalling system, i.e.
sgp130 and sIL-6R, might give additional mechanistic insights into
the atherosclerotic process associated with STEMI.
The aims of the present study were to elucidate possible associa-
tions between members of the IL-6 transsignalling system including
sIL-6R and sgp130 and (1) the degree of myocardial necrosis, (2) left
ventricular (LV) impairment, and (3) dysglycemia as well as conven-




This study was a cross-sectional cohort study of STEMI patients
admitted to Oslo University Hospital Ullevål, Norway and treated
with primary PCI. From June 2007 to August 2011 a total of 1028
patients with diagnosed STEMI were included consecutively dur-
ing weekdays after written informed consent was obtained. The
study was approved by the Regional Ethics Committee.
STEMI was deﬁned as electrocardiographic ST segment eleva-
tion of >2mm in two or more contiguous chest leads or >1mm in
two or more limb leads or new onset of left bundle-branch block,
together with chest pain or other typical symptoms and elevated
troponin levels above the 99th percentile.
Patients below 18 years old or patients unable or unwilling to
give written informed consent were not included. Patients were
routinely included after the primary PCI-procedure, the following
morning after the admission.
Clinical information was collected from hospital records and
questionnaires obtained at the time of inclusion.
2.2. Laboratory methods
Blood samples were collected at median time of 24 h after
symptoms and 18 h after the PCI procedure, between 08:00 and
10:00 a.m. the following morning, except those with infarction
during the weekend, which were included the following monday
morning. In order to standardize blood sampling, and also to avoid
any inﬂuence of diurnal variations and food intake, all samples
were taken after an overnight fast. Serum was prepared by
centrifugation for 10min at 2000g and samples were stored at
80 1C until analysed. Circulating levels of sgp130, sIL-6R and IL-6
were determined by commercial ELISA (R&D Systems, Abingdon,
Oxon, UK) and CRP with kits from DRG Instruments (Marburg/
Lahn, Germany). In our laboratory, the inter-assay coefﬁcients of
variation (CV) were 5.2%, 3.6%, 10.5% and o5%.
Routine blood samples were analysed by use of commercial
methods. Electrochemiluminescence technology for quantitative mea-
surement was used for repeated measures of TnT (3rd generation
cTroponinT, Elecsys 2010, Roche, Mannheim, Germany). The lower
detection limit of the assay is 10 ng/L with a recommended diagnostic
threshold of 30ng/L. The inter-assay coefﬁcient of variation was 7%.
TnT levels were determined in blood samples collected immediately
after the acute PCI and in repetitive samples with 4 h between the two
ﬁrst samples and then following every 12h until a rise and fall curve
was observed. The level used in this study was the highest measured
during hospital stay for each patient.
NT-proBNP was measured in serum using Elecsys proBNP
sandwich immunoassay on Elecsys 2010 (Roche Diagnostics,
Indianapolis, USA). The inter-assay coefﬁcient of variation was 7%.
2.3. Left ventricular function
Left ventricular ejection fraction (LVEF) was measured by echocar-
diography a.m. Simpson or by visual judgement before hospital
discharge or at clinical follow-upwithin 3months after the myocardial
infarction. In case of repeated examinations, an average value was
used. LVEF obtained after discharge was only included if the patient
was hemodynamically stable and without rehospitalisation between
the index myocardial infarction and the examination.
2.4. Statistics
Continuous variables are presented as median values (25, 75
percentiles) and categorical variables as proportions.
As most measured biomarkers were skewly distributed, non-
parametric methods were used throughout. Correlation analyses
were performed by Spearman's rho and the Mann–Whitney test
was used for group comparisons.
The 75th percentile was chosen as cut-off points for max TnT and
NT-proBNP in the present material. The LVEF cut-off level was set to
40% according to clinical practice. Glucometabolic classiﬁcation was
deﬁned according to the American Diabetes Association criteria [12].
We dichotomised the following variables into high and low values
using cut-off levels of 11.1mmol/L for admission glucose, 7.0mmol/L
for fasting glucose, and 6.5% for HbA1c. A p-value of o0.05 was
considered statistically signiﬁcant. All analyses were performed by
SPSS Software, version 18.0 (SPSS Inc., USA).
3. Results
Baseline characteristics of the total study population (n ¼
1028) are shown in Table 1. The cohort was relatively young
(median 61 years) with medium size infarction (measured by peak
TnT), 80% were male and 47% were current smokers. Only 12% had
previous myocardial infarction, 13% had known diabetes. Half of
the patients had single vessel disease.
The included patients were on average hemodynamically stable
with only slightly reduced LVEF and normal NT-proBNP levels.
3.1. Circulating levels of IL-6, gp130, IL-6R and CRP
There were weak, but statistically signiﬁcant correlations between
age and IL-6 and between systolic blood pressure and IL-6, sgp130 and
sIL-6R (Table 2). IL-6 and CRP, as well as sgp130 and sIL-6R, were
signiﬁcantly intercorrelated (p o 0.001, all), however, the correlation
between sgp130 and sIL-6R was weak (Table 2). There was no
correlation between IL-6 and sIL-6R while there was a weak, inverse
correlation between CRP and sIL-6R (p ¼ 0.001). Smokers had
signiﬁcant lower levels of sgp130 levels compared to non-smokers,
whereas no gender differences were found (Table 3).
3.2. Association with max troponin T
There were signiﬁcant correlations between peak TnT and IL-6,
and between peak TnT and CRP (Table 2). When dichotomising TnT
values at the 75th percentile (7140 ng/L) (quartiles shown in
Fig. 1), IL-6 and CRP were found to be signiﬁcantly elevated in
the upper quartiles compared to the lower three quartiles (p o
0.001, both) (Table 3). On the other hand no associations were
found between peak TnT levels and sgp130 or sIL-6R levels
(Tables 2 and 3, Fig. 1).
3.3. Association with LVEF and NT-proBNP
We found signiﬁcant inverse correlations between LVEF and
levels of IL-6, sgp130 and CRP. There were also signiﬁcant correla-
tions between NT-proBNP levels and IL-6 and CRP (Table 2).
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When dichotomized into groups of high (Z40%) and low LVEF,
we found signiﬁcantly elevated levels of IL-6 and CRP in the lower
LVEF group (Table 3). When dichotomizing NT-proBNP at the 75th
percentile (Z122 ng/L), IL-6, sgp130 and CRP were signiﬁcantly
elevated in the upper quartile compared to the lower three
quartiles (po0.01, all) (Table 3). However sIL-6R was neither
associated with LVEF nor with NT-proBNP levels (Table 3).
3.4. Association with glucometabolic state
Weak, but statistically signiﬁcant correlations were found for
sgp130 and CRP levels and both HbA1c and admission glucose
(Table 2). IL-6, sgp130 and CRP were also signiﬁcantly correlated to
fasting glucose levels (Table 2). Dichotomized into groups of known
diabetes or not, high (Z6.5%) or low HbA1c levels, high (Z11.1mmol/
L) or low admission-glucose, and high (Z7.0mmol/L) or low fasting
glucose levels, sgp130 and CRP levels were signiﬁcantly elevated in the
groups of patients with known diabetes, and high HbA1c and glucose
levels (Table 3). IL-6 was signiﬁcantly elevated in the group of high
admission glucose levels only. sIL-6R did not show any association to
the glucometabolic state (Table 3).
4. Discussion
The main results of the present study were that patients with the
most extensive myocardial necrosis deﬁned as the upper quartile of
peak TnT, had elevated circulating levels of IL-6 and CRP, whereas
levels of circulating receptor and receptor unit, sIL-6R and sgp130,
were not related to the degree of myocardial necrosis. Furthermore, IL-
6, sgp130 and CRP were elevated in patients with high NT-proBNP
levels and IL-6 and CRP were associated with reduced LVEF. Finally,
circulating levels of sgp130 were signiﬁcantly elevated in STEMI
patients with diabetes and were associated with glucometabolic
variables measured during the acute STEMI.
Neither CRP, sgp130 nor sIL-6R were associated with age or gender
in this STEMI population. IL-6 was weakly associated with age, and
interestingly, smokers had signiﬁcantly reduced sgp130 levels, which
to our knowledge has not previously been shown. This is not easily
explainable, but it might ﬁt with the assumption that sgp130 has
antiinﬂammatory properties [7] and that smokers are prone to
inﬂammation. When we compared the measured inﬂammatory
biomarkers to each other, IL-6 was signiﬁcantly correlated to CRP as
expected. However sgp130 and sIL-6R were weakly intercorrelated,
whereas sIL-6R was weakly inversely correlated to CRP. As sgp130may
act as an inhibitor of the sIL-6R/IL-6 complex [7,13], binding of sgp13
may inhibit the activation of the transsignalling cascade, and thereby
possibly reducing the levels of CRP.
The relation between IL-6, CRP and myocardial necrosis or
infarct size is well known. Our results showing an association
between IL-6 and CRP with high levels of peak TnT are thus in
accordance with other studies, conﬁrming the connection
between inﬂammation and infarct size [6,14,15]. A novel observa-
tion in STEMI patients was the lack of association between peak
TnT and sgp130 or sIL-6R. There is limited knowledge of the role of
these circulating members of the IL-6 receptor complex in patients
with STEMI. Signiﬁcantly higher levels of sIL-6R in a group of
patients with acute myocardial infarction compared to stable
angina patients and controls has been reported [16]. In contrast,
in the study of Kaminski et al., no differences were observed in the
levels of neither sIL-6R nor sgp130 in patients with myocardial
infarction (MI) compared to patients with stable angina or healthy
controls [17]. They showed, however, a possible relation between
concentrations of IL-6 and sIL-6R in the coronary sinus and
cardiovascular complications in patients with MI [17]. The levels
of sIL-6R and sgp130 in this study were of similar magnitude as
was found in the present study. There is limited knowledge on
sgp130 levels in MI patients, although an inverse association
between sgp130 levels and CRP has been demonstrated [18],
indicating high levels of sgp130 to be protective in this setting.
One might speculate that the complex orchestration of the IL-6
Table 1
Baseline characteristics.
Patients (n ¼ 1028)
Age (years)a 61 (24/94)
Male 823 (80)
Weight (kg) 83 (74, 93)
Waist circumference (cm) 97 (90, 104)
Systolic blood pressure (mmHg) 140 (120, 157)
Smokers 485 (47.2)
Previous disorders
Angina pectoris 88 (8.6)
Myocardial infarction 125 (12.2)
Hypertension 351 (34.1)
Heart failure 20 (1.9)
Cerebrovascular disease 47 (4.6)
Diabetes mellitus 132 (12.8)
Insulin treated diabetes 33 (3.2)
Atrial ﬁbrillation 42 (4.1)
Laboratory analyses at admission
Hemoglobin (g/100 mL) 13.4 (12.6, 14.3)
Total cholesterol (mmol/L) 4.8 (4.1, 5.6)
Triglycerides (mmol/L) 1.3 (0.9, 1.8)
Admission glucose (mmol/L) 7.4 (6.3, 9.0)
Fasting glucose (mmol/L) 5.8 (5.2, 6.7)
HbA1c (%) 5.9 (5.6, 6.3)
TnT max (ng/L) 3800 (1710, 7140)
NT-proBNP (ng/L) 33 (11, 122)
Prehospital thrombolysis 119 (11.6)
Time interval from symptoms to
blood sampling (h)a
24 (2/264)
Anterior infarction 438 (42.6)




LVEF ( %)b 50 (44, 55)
Data are presented as median (25, 75 percentiles) or numbers ( %) if not otherwise
stated, for details see Section 2.
a Range.
b Left ventricular ejection fraction.
Fig. 1. Inﬂammatory biomarkers related to TnT levels. The different variables (IL-6,
sgp130, sIL-6R and CRP) as related to quartiles of peak TnT Levels are given as
median values with interquartile range.
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system does not happen in the acute phase, but might – especially
in the case of sgp130 – happen after the initial burst of pro-
inﬂammatory stimuli as an anti-inﬂammatory compensatory
mechanism in the subacute phase after AMI. It should also be
emphasized that the variables measured in the circulation may not
reﬂect or correlate to the tissue consentration.
The importance of inﬂammation in congestive heart failure has
been consistently reported over the last decades. Our results,
showing signiﬁcantly elevated levels of IL-6 and CRP in patients
with high NT-proBNP values and low LVEF, are consistent with
other reports [6,19]. We found no direct correlation between
sgp130 and NT-proBNP, but when NT-proBNP was dichotomised
Table 2
Correlation between inﬂammatory biomarkers and patients characteristics.
IL-6 sgp130 sIL-6R CRP
Age 0.095, 0.002 0.05, 0.106 0.002, 0.953 0.032, 0.311
Systolic BPa 0.139, o0.001 0.081, 0.01 0.069, 0.028 0.23, 0.458
TnT max 0.282, o0.001 0.06, 0.054 0.051, 0.106 0.302, o0.001
NT-proBNP 0.217, o0.001 0.058, 0.066 0.020, 0.535 0.328, o0.001
LVEFb 0.189, o0.001 0.085, 0.018 0.018, 0.610 0.274, o0.001
HbA1c 0.059, 0.065 0.092, 0.004 0.036, 0.264 0.064, 0.045
Admission glucose 0.058, 0.063 0.132, o0.001 0.032, 0.307 0.067, 0.032
Fasting glucose 0.124, o0.001 0.082, 0.009 0.028, 0.370 0.133, o0.001
Timec 0.077, 0.014 0.049, 0.119 0.109. o0.001 0.452, o0.001
IL-6 1 0.042, 0.176 0.007, 0.832 0.418, o0.001
sgp130 – 1 0.182, o0.001 0.040, 0.205
sIL-6R – – 1 0.103, 0.001
CRP – – – 1
Data are presented as coefﬁcients of correlation and p-values.
a Systolic blood pressure.
b Left ventricular ejection fraction.
c Time interval from symptom onset to blood sampling in hours.
Table 3
Circulating levels of the IL-6 family members in STEMI patients (n ¼ 1028), related to patient characteristics.
IL-6 pg/mL sgp130 ng/mL sIL-6R ng/mL CRP mg/L
Female 19.4 (13.3, 31.4) 240 (218, 264) 39,1 (30.9, 46.9) 16.3 (8.2, 38.3)
Male 18.7 (14.1, 29.8) 240 (219, 259) 39.4 (31.2, 47.8) 13.0 (6.9, 31.1)
p-Value 0.7 0.09 0.9 0.09
No smokers 18.5 (14.1, 29.3) 244 (222, 265) 39.3 (31.5, 47.7) 12.0 (6.2, 34.2)
Smokers 19.1 (13.8, 30.2) 238 (217, 258) 39.2 (30.8, 47.5) 14.2 (7.1, 31.5)
p-Value 0.5 0.005 0.7 0.2
Low TnT maxa 18.0 (13.2, 26.2) 240 (217, 259) 39.7 (30.9, 47.8) 11.7 (6.2, 26.5)
High TnT max 25.0 (17.3, 36.5) 240 (222, 265) 38.6 (31.3, 47.3) 22.1 (10.5, 49.5)
p-Value o0.001 0.2 0.8 o0.001
Low NT-proBNPb 18.1 (13.0, 26.8) 238 (218, 258) 39.4 (31.1, 48.1) 11.6 (6.0, 23.3)
High NT-proBNP 24.3 (17.4, 34.5) 246 (221, 268) 38.7 (30.4, 46.3) 31.1 (11.6, 82.0)
p-Value o0.001 0.007 0.2 o0.001
LVEF o40% 29.0 (17.9, 37.5) 240 (223, 265) 37.9 (29.5, 49.1) 36.1 (4.11, 9.5)
LVEF Z40% 18.6 (13.3, 29.0) 239 (218, 259) 39.3 (30.9, 47.3) 13.3 (6.8, 29.4)
p-Value o0.001 0.2 0.8 o0.001
No diabetics 18.7 (14.1, 29.7) 239 (218, 259) 39.2 (31.2, 47.5) 13.1 (7.0, 31.0)
Diabetics 19.1 (12.7, 33.7) 247 (226, 270) 39.7 (30.6, 47.8) 16.6 (7.5, 58.5)
p-Value 0.5 0.002 1.0 0.04
Low HbA1cc 18.6 (14.0, 29.0) 238 (217, 258) 39.1 (30.9, 47.4) 13.1 (6.9, 30.7)
High HbA1c 20.0 (13.9, 33.3) 246 (229, 273) 40.6 (31.7, 47.9) 17.0 (7.8, 49.6)
p-Value 0.056 o0.001 0.4 0.03
Low admission glucosed 18.7 (13.9, 29.2) 239 (218, 260) 39.2 (31.2, 47.6) 12.8 (6.9, 29.3)
High admission glucose 20.6 (15.6, 34.8) 246 (224, 273) 39.1 (30.3, 49.1) 23.3 (10.2, 68.9)
p-Value 0.016 0.02 0.7 o0.001
Low fasting glucosee 18.7 (13.9, 29.0) 239 (218, 259) 39.2 (30.9, 47.6) 12.7 (6.9, 29.2)
High fasting glucose 19.7 (14.3, 33.8) 243 (220, 270) 39.3 (31.7, 47.2) 18.3 (8.4, 52.8)
p-Value 0.07 0.05 0.7 o0.001
Medians (25,75 percentiles) are given.
a TnT max low o7140 ng/L and high Z7140 ng/L.
b Low NT-proBNP o122 ng/L and high Z122 ng/L.
c Low HbA1c o6.5% and high Z6.5%.
d Low admission glucose o11.1 mmol/L and high Z11.1 mmol/L.
e Low fasting glucose o7.0 mmol/L and high Z7.0 mmol/L.
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at the 75th percentile, we found signiﬁcantly elevated levels of
sgp130 in the upper quartile vs. the lower three quartiles. This may
reﬂect an up regulation of sgp130 in patients with failing post-
ischemic myocardium, as also suggested by others [20]. This
association, which seems to be independent of the extent of
myocardial necrosis, is to our knowledge not previously described
in STEMI patients. However, sgp130 levels were not related to low
LVEF. It has previously also been shown that elevated sgp130 levels
are associated with cardiovascular mortality and death from
worsening of heart failure [21] as well as with the severity of
congestive heart failure [20,22]. No signiﬁcant association
between sIL-6R and heart failure could be demonstrated in our
population. This is in line with a previous report [20].
There are to our knowledge no previous reports of the association
between sgp130 and glucometabolic disturbances in a STEMI popula-
tion. We found signiﬁcantly higher levels of sgp130 in STEMI patients
with known diabetes or high HbA1c values. Signiﬁcant, although weak
correlations were also found between sgp130 and both admission
glucose, and fasting glucose. It is possible that MI patients with
impaired glucose regulation have increased sgp130 levels related to
insulin resistance and endothelial dysfunction, although this hypoth-
esis must be investigated in further studies. The association regarding
fasting glucose should be interpreted with caution as glucose levels in
the acute phase might be inﬂuenced by myocardial necrosis or
inﬂammation. A possible inﬂuence of glucose per se should never-
theless be further explored. A signiﬁcant relationship between sgp130
and the metabolic syndrome and insulin resistance discussed to be
related to endothelial dysfunction, has previously been reported
[23,24]. Again, a compensatory up-regulation of sgp130 might be
suggested.
5. Limitations
One limitation in our study is the lack of repeated blood sampling
in order to study the time-course of the measured variables. Also the
variability in the time frame from symptoms onset to blood sampling
may play a role. We do not know, from the present study, the time
proﬁle of sgp130 and sIL-6R after a STEMI and we may have missed
both a peak value as well as possible transient changes, as discussed in
previous reports [25,26].
There was, however, a relatively large number of patients included
with relatively large differences in both time from symptoms and time
from PCI, to blood sampling and any correlations between time and
measured parameters were weak except for CRP, suggesting that the
measured variables were representative for the levels in a broad
population of patients with PCI treated STEMI.
The median time from start of symptoms to blood sampling
was 24 h. IL-6 was weakly correlated to time, which is in
accordance with other reports describing peak IL-6 in patients
with STEMI occurring after the ﬁrst day [27,28]. For CRP there was
a stronger association between time from start of symptoms to
blood sampling and the measured levels, despite the fact that peak
CRP value may occur as late as 72 h after PCI [27,28]. Secondly, our
STEMI cohort was a low-risk population with subnormal LVEF and
few complications, which may have inﬂuenced the results.
6. Conclusion
In our STEMI-population circulating levels of IL-6 and CRP were
elevated in patients with high peak TnT, conﬁrming previous
reports. In contrast we found no association between circulating
levels of gp130 or IL-6R and myocardial necrosis. Finally sgp130
levels were weakly, but statistically signiﬁcantly associated with
measures of heart failure and glucometabolic disturbance and sIL-
6R did not show any associations with these parameters.
The biological importance of the IL-6/IL-6R/gp130-mediated
transsignalling pathway in patients with acute myocardial infarc-
tion and dysglycemia should be further elucidated.
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